Glenmark Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Glenmark Pharmaceuticals has a total shareholder equity of ₹97.4B and total debt of ₹51.8B, which brings its debt-to-equity ratio to 53.2%. Its total assets and total liabilities are ₹200.1B and ₹102.7B respectively. Glenmark Pharmaceuticals's EBIT is ₹11.2B making its interest coverage ratio 2.5. It has cash and short-term investments of ₹11.2B.
Key information
53.2%
Debt to equity ratio
₹51.82b
Debt
Interest coverage ratio | 2.5x |
Cash | ₹11.24b |
Equity | ₹97.36b |
Total liabilities | ₹102.71b |
Total assets | ₹200.06b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 532296's short term assets (₹112.7B) exceed its short term liabilities (₹58.4B).
Long Term Liabilities: 532296's short term assets (₹112.7B) exceed its long term liabilities (₹44.3B).
Debt to Equity History and Analysis
Debt Level: 532296's net debt to equity ratio (41.7%) is considered high.
Reducing Debt: 532296's debt to equity ratio has reduced from 75% to 53.2% over the past 5 years.
Debt Coverage: 532296's debt is not well covered by operating cash flow (13.9%).
Interest Coverage: 532296's interest payments on its debt are not well covered by EBIT (2.5x coverage).